Glenview Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$71.2M |
| 2 |
Humana
HUM
|
+$68.6M |
| 3 |
Cigna
CI
|
+$60.7M |
| 4 |
Uber
UBER
|
+$57.6M |
| 5 |
Centene
CNC
|
+$55.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$324M |
| 2 |
DigitalOcean
DOCN
|
+$111M |
| 3 |
Tenet Healthcare
THC
|
+$96.7M |
| 4 |
Expedia Group
EXPE
|
+$91.1M |
| 5 |
Knight Transportation
KNX
|
+$76.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 45.27% |
| 2 | Technology | 18.54% |
| 3 | Industrials | 11.89% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Communication Services | 4.2% |
Similar funds
Glenview Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Glenview Capital Management held 66 positions worth $3.98B, down 19% from $4.91B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Glenview Capital Management withdrew a net $600M in Q1 2026, closing 22 positions and reducing 15 holdings. Its most notable exit was Expedia Group, an estimated $91.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 48% a quarter earlier, followed by Technology and Industrials.
Against the trend, Glenview Capital Management opened a new position in Humana worth $58.1M.
- Glenview Capital Management's largest Q1 2026 buy was Humana: 334,892 shares worth $58.1M.
- Glenview Capital Management added most to Meta Platforms (Facebook) in Q1 2026, an estimated $71.2M increase.
- Glenview Capital Management's biggest Q1 2026 reduction was Teva Pharmaceuticals, cutting an estimated $324M.
- Glenview Capital Management fully exited Expedia Group in Q1 2026, selling an estimated $91.1M.
- Glenview Capital Management's ten largest holdings make up 61% of its $3.98B portfolio in Q1 2026.
- Glenview Capital Management opened 9 new positions and closed 22 in Q1 2026.
- Glenview Capital Management's portfolio value fell 19% quarter-over-quarter to $3.98B.
Based on Glenview Capital Management's 13F filing for Q1 2026, filed 15 May 2026.